close

Clinical Trials

1 2 3 4 210
Number of results: 4199

Excel print is not allowed for data more than 300.Please search above for fewer data.

Date Product Disease Phase Company Therapeutic area
2018-01-08 MAGE A10c796T - autologous genetically modified T-cells expressing enhanced T cell receptors (TCRs) specific for MAGE A10 locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC) 1-2 Adaptimmune (UK) Cancer - Oncology
2018-01-08 ACE 083 facioscapulohumeral muscular dystrophy (FSHD) 2 Acceleron Pharma (USA - CA) Rare diseases - Genetic diseases - Neuromuscular diseases
2018-01-05 ISIS 678354 (AKCEA-APOCIII-LRx) patients with hypertriglyceridemia and established cardiovascular disease 2b Akcea Therapeutics (USA - CA), a subsidiary of Ionis Pharmaceuticals (USA - CA) Cardiovascular diseases
2018-01-05 M281 autoimmune diseases 1 Momenta Pharmaceuticals (USA - MA) Autoimmune diseases
2018-01-04 BioChaperone® glucagon exenatide obesity Adocia (France) Metabolic diseases
2018-01-04 BioChaperone® teduglutide short bowel syndrome Adocia (France) Rare diseases - Gastrointestinal diseases
2018-01-04 ABX464 ulcerative colitis 2a Abivax (France) Autoimmune diseases - Inflammatory diseases - Digestive diseases
2018-01-03 BAL101553 in combination with standard radiation newly-diagnosed glioblastoma 1 Basilea Pharmaceutica (Switzerland) Adult Brain Tumor Consortium (ABTC) (USA) Cancer - Oncology
2018-01-03 solid tumors including advanced or metastatic breast, ovarian, endometrial and urothelial carcinomas 1 Five Prime Therapeutics (USA - CA) Cancer - Oncology
2018-01-03 BAL101553 advanced solid tumors including glioblastoma 2a Basilea Pharmaceutica (Switzerland) Cancer - Oncology
2018-01-02 tabelecleucel (formerly known as ATA129) rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD) 3 Atara Biotherapeutics (USA - CA) Cancer - Oncology
2018-01-02 tislelizumab (BGB-A317) hepatocellular carcinoma 3 BeiGene (China) Cancer - Oncology
2018-01-02 FPA144 in combination with mFOLFOX6 previously untreated, advanced gastric or gastroesophageal cancer 1-3 Five Prime Therapeutics (USA - CA) Cancer - Oncology
2017-12-29 HyLeukin® advanced solid tumors 1b Genexine (Republic of Korea) Cancer - Oncology
2017-12-28 ADVM-043 alpha-1 antitrypsin (A1AT) deficiency 1-2 Adverum Biotechnologies (USA - CA) Rare diseases - Genetic diseases
2017-12-27 Iomab-B (131I apamistamab) acute myeloid leukemia (AML) 3 Actinium Pharmaceuticals (USA - NJ) Cancer - Oncology
2017-12-27 imeglimin type 2 diabetes 3 Poxel (France) Sumitomo Dainippon Pharma (Japan) Metabolic diseases
2017-12-27 Kevetrin® (thioureidobutyronitrile), ovarian cancer 2 Cellceutix (USA - MA) now Innovation Pharmaceuticals (USA - MA) Cancer - Oncology
2017-12-27 locally advanced cutaneous melanoma Provectus Pharmaceuticals (USA - TN) Cancer - Oncology
2017-12-27 VB-111 (ofranergene obadenovec) platinum-resistant ovarian cancer 3 VBL Therapeutics (Israel) Cancer - Oncology